Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
about
Emerging therapeutic biomarkers in endometrial cancerOrally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinibPersonalized targeted therapy for lung cancerRecent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells.Therapy-induced enrichment of putative lung cancer stem-like cells.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.Emerging drugs for endometrial cancer.Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer.Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].Utilization of lung cancer cell lines for the study of lung cancer stem cells.
P2860
Q26865904-9D7EF6EA-1672-4CEB-B696-8AD623D815BFQ33654186-EEA94638-58D8-44D6-BC66-ABA0FD2D1863Q36321826-20706F76-9593-49BE-B382-271CE1F93309Q38023942-A638640D-D33B-4D7E-9F55-D6B9FA4A30CCQ38086010-6B5C70E1-4916-4BCF-8F60-1C22AC69EBEAQ38150766-1FC9AA91-57A4-49E7-AD33-25EB0966639EQ38168795-3AF80AB5-C75A-4DFF-BF29-81DA585B166CQ38261469-AA1556F2-9D58-4464-AF9C-F1FF9315FD79Q47130408-B999CAA0-D659-45A7-83C7-21D91D4E3CDFQ47754114-23F9D6CB-F8B6-409C-B47F-DCE481C9DE02Q52565512-5B245162-D3BD-452D-80C5-6A4D39BDB313Q53698558-8C0421A1-E251-4F4C-8CB1-5789D329C4EEQ54279044-40BC0A23-DEF7-4686-AD95-06124CCAD741Q55368577-E4234B25-CC7E-484F-A276-AE4F618061F7
P2860
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Properties of resistant cells ...... treated with EGFR inhibitors.
@ast
Properties of resistant cells ...... treated with EGFR inhibitors.
@en
Properties of resistant cells ...... treated with EGFR inhibitors.
@nl
type
label
Properties of resistant cells ...... treated with EGFR inhibitors.
@ast
Properties of resistant cells ...... treated with EGFR inhibitors.
@en
Properties of resistant cells ...... treated with EGFR inhibitors.
@nl
prefLabel
Properties of resistant cells ...... treated with EGFR inhibitors.
@ast
Properties of resistant cells ...... treated with EGFR inhibitors.
@en
Properties of resistant cells ...... treated with EGFR inhibitors.
@nl
P2860
P356
P1433
P1476
Properties of resistant cells ...... treated with EGFR inhibitors.
@en
P2093
Gargi Ghosh
Sean P Palecek
P2860
P2888
P356
10.1186/1471-2407-12-95
P407
P577
2012-03-20T00:00:00Z
P5875
P6179
1005265389